The variability in clinical presentation highlights the importance of genetic characterization in managing the disease effectively, not only for β-thalassaemia, Hb E, but also for α0 deletions and severe α+ mutations that may cause severe Hb H disease. The gene discussed is GSTM1; the disease is thalassemia.